Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2032471rdf:typepubmed:Citationlld:pubmed
pubmed-article:2032471lifeskim:mentionsumls-concept:C0278488lld:lifeskim
pubmed-article:2032471lifeskim:mentionsumls-concept:C0348013lld:lifeskim
pubmed-article:2032471lifeskim:mentionsumls-concept:C0042670lld:lifeskim
pubmed-article:2032471lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:2032471lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:2032471pubmed:issue2lld:pubmed
pubmed-article:2032471pubmed:dateCreated1991-6-24lld:pubmed
pubmed-article:2032471pubmed:abstractTextIn 19 patients with advanced pretreated breast cancer, vinblastine was administered by continuous venous infusion (2 mg/m2/24 h for 120 h every 3 weeks), using a totally implanted venous access and a portable pump. A total of 55 courses were given. Five objective responses were observed. Drug-related toxicity consisted mainly of leukopenia (4 patients), fever (4 patients) and nausea and vomiting (3 patients). Catheter-related toxicity was observed in 4 patients (21%) and consisted of infection of the skin pocket in 1 patient and dislodging of the needle with drug extravasation in 3 patients.lld:pubmed
pubmed-article:2032471pubmed:languageenglld:pubmed
pubmed-article:2032471pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2032471pubmed:citationSubsetIMlld:pubmed
pubmed-article:2032471pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2032471pubmed:statusMEDLINElld:pubmed
pubmed-article:2032471pubmed:issn0009-3157lld:pubmed
pubmed-article:2032471pubmed:authorpubmed-author:RossiLLlld:pubmed
pubmed-article:2032471pubmed:authorpubmed-author:PronzatoPPlld:pubmed
pubmed-article:2032471pubmed:authorpubmed-author:BertelliGGlld:pubmed
pubmed-article:2032471pubmed:authorpubmed-author:AmorosoDDlld:pubmed
pubmed-article:2032471pubmed:authorpubmed-author:SertoliM RMRlld:pubmed
pubmed-article:2032471pubmed:authorpubmed-author:VidiliM GMGlld:pubmed
pubmed-article:2032471pubmed:authorpubmed-author:QueiroloPPlld:pubmed
pubmed-article:2032471pubmed:issnTypePrintlld:pubmed
pubmed-article:2032471pubmed:volume37lld:pubmed
pubmed-article:2032471pubmed:ownerNLMlld:pubmed
pubmed-article:2032471pubmed:authorsCompleteYlld:pubmed
pubmed-article:2032471pubmed:pagination146-9lld:pubmed
pubmed-article:2032471pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:meshHeadingpubmed-meshheading:2032471-...lld:pubmed
pubmed-article:2032471pubmed:year1991lld:pubmed
pubmed-article:2032471pubmed:articleTitleContinuous venous infusion of vinblastine in metastatic breast cancer.lld:pubmed
pubmed-article:2032471pubmed:affiliationIstituo Nazionale per la Ricerca sul Cancro, Genova, Italia.lld:pubmed
pubmed-article:2032471pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2032471pubmed:publicationTypeClinical Triallld:pubmed